Empirical Asset Management LLC Acquires 1,252 Shares of Eli Lilly and Company $LLY

Key Points

• Empirical Asset Management increased its Eli Lilly stake by 36.7% in the second quarter, acquiring 1,252 shares and bringing its total to 4,661 shares valued at $5.59 million. Institutional investors own approximately 82.53% of LLY.
• Wall Street remains broadly bullish, with 24 Buy ratings, one Strong Buy, four Holds and one Sell; the average price target is $1,292.18. LLY recently traded at $1,247.92, near its 12-month high of $1,292.65.
• Eli Lilly exceeded quarterly expectations, reporting $8.38 in earnings per share and $22.97 billion in revenue, up 47.7% year over year. The company also declared a quarterly dividend of $1.73, equivalent to a 0.6% annualized yield.

Empirical Asset Management LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 36.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,661 shares of the company's stock after acquiring an additional 1,252 shares during the period. Eli Lilly and Company accounts for approximately 1.3% of Empirical Asset Management LLC's holdings, making the stock its 11th biggest holding. Empirical Asset Management LLC's holdings in Eli Lilly and Company were worth $5,591,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Sound Financial Strategies Group LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $203,000. Chancellor Financial Group WB LP boosted its stake in Eli Lilly and Company by 1.7% during the second quarter. Chancellor Financial Group WB LP now owns 918 shares of the company's stock worth $1,101,000 after buying an additional 15 shares during the period. Richardson Financial Services Inc. increased its position in Eli Lilly and Company by 2.4% during the second quarter. Richardson Financial Services Inc. now owns 733 shares of the company's stock valued at $879,000 after acquiring an additional 17 shares during the last quarter. Avaii Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 110.0% in the second quarter. Avaii Wealth Management LLC now owns 1,665 shares of the company's stock valued at $1,998,000 after acquiring an additional 872 shares during the period. Finally, Compass Wealth Management LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $7,308,000. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on LLY shares. The Goldman Sachs Group reiterated a "buy" rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Wall Street Zen cut Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Sunday. Guggenheim increased their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Finally, Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $1,292.18.

Eli Lilly and Company Price Performance

LLY opened at $1,247.92 on Tuesday. The company has a market capitalization of $1.17 trillion, a price-to-earnings ratio of 41.88, a PEG ratio of 1.48 and a beta of 0.51. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 12-month low of $694.23 and a 12-month high of $1,292.65. The business's fifty day simple moving average is $1,182.50 and its 200-day simple moving average is $1,061.66.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the company posted $6.31 earnings per share. The firm's quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is currently 23.22%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA cleared an Alzheimer’s blood test developed by Roche and Eli Lilly to help identify signs of the disease in people aged 55 and older who have cognitive decline. The approval expands Lilly’s potential presence in Alzheimer’s diagnostics and supports its broader neuroscience strategy. Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance
• Positive Sentiment: Lilly launched its once-daily oral weight-loss and diabetes treatment Foundayo, or orforglipron, in U.K. pharmacies. The European rollout gives patients an alternative to injectable GLP-1 drugs and provides a new commercial growth opportunity in the expanding obesity-treatment market. Eli Lilly launches oral weight-loss pill Foundayo in UK
• Positive Sentiment: Citadel, led by Ken Griffin, reportedly nearly quadrupled its Eli Lilly position in the second quarter, building a stake valued at approximately $1.1 billion. The move may reinforce investor confidence in Lilly’s diabetes, obesity and pipeline growth prospects. Eli Lilly Stock in Focus as Hedge Fund Titan Ken Griffin Quadruples Position
• Neutral Sentiment: Analysts and investor commentary continue to highlight the possibility of $100 billion-plus annual revenue, supported by GLP-1 demand and upcoming pipeline catalysts. However, those expectations are already reflected in Lilly’s roughly $1.17 trillion market capitalization, raising the bar for further gains.
• Negative Sentiment: Healthcare stocks broadly weakened during afternoon trading, creating sector-wide pressure on Lilly independent of company-specific developments. Sector Update: Healthcare Stocks Decline in Afternoon Trading
• Negative Sentiment: Lilly’s retreat also reflects profit-taking and valuation sensitivity after a major rally. Investors may be questioning whether extraordinary growth in obesity drugs can continue to justify the company’s elevated valuation amid intensifying competition from Novo Nordisk and other emerging treatments. Eli Lilly Slips as Its Valuation Cools

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source